Related Experiment Video

Updated: May 10, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Carcinogenesis of PIK3CA

Sidra German1, Hafiz Muhammad Aslam, Shafaq Saleem

  • 1Final year student of Dow University of Health Sciences, Karachi, Pakistan. coolaslam8@hotmail.com.

Hereditary Cancer in Clinical Practice
|June 18, 2013
PubMed

Insights

The PIK3CA gene is frequently altered in many cancers, controlling crucial cell functions. Inhibiting the PI3K pathway offers promising therapeutic strategies for various carcinomas.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The PIK3CA gene, encoding phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha, is the most frequently mutated oncogene in human cancers.
  • Alterations in PIK3CA are common in endometrial, ovarian, colorectal, breast, and other cancers, impacting cell growth, proliferation, and survival.

Purpose of the Study:

  • To highlight the significance of PIK3CA mutations in human cancers.
  • To discuss the therapeutic potential of inhibiting the PI3K signaling pathway.

Main Methods:

  • Review of existing literature on PIK3CA mutations and PI3K pathway inhibitors.
  • Analysis of the role of PIK3CA in cancer development and progression.

Main Results:

  • PIK3CA mutations are prevalent across a wide spectrum of human malignancies.
  • Inhibition of PI3K signaling demonstrates efficacy in reducing cancer cell proliferation and promoting cell death.

Conclusions:

  • PIK3CA is a critical oncogene and a validated target for cancer therapy.
  • Various PI3K pathway inhibitors, including pan-PI3K, isoform-specific inhibitors, and dual PI3K-mTOR inhibitors, are advanced in clinical development and approved for treating several carcinomas.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...